9667244

Source:http://linkedlifedata.com/resource/pubmed/id/9667244

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006826, umls-concept:C0008976, umls-concept:C0030705, umls-concept:C0205390, umls-concept:C1511481, umls-concept:C2587213, umls-concept:C2603343
pubmed:issue	7
pubmed:dateCreated	1998-8-12
pubmed:abstractText	To address the challenging ethical dilemmas created from the participation of advanced cancer patients in phase I trials, we assessed the feasibility of a clinical trial design that uses an interactive informed consent process in which patient-subjects can choose to become directly involved in decisions of dose escalation.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 14599
pubmed:keyword	http://linkedlifedata.com/resource/pubmed/keyword/Biomedical and Behavioral Research, http://linkedlifedata.com/resource/pubmed/keyword/Empirical Approach, http://linkedlifedata.com/resource/pubmed/keyword/UNIVERSITY OF CHICAGO
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	E
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine, http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0732-183X
pubmed:author	pubmed-author:BanikD MDM, pubmed-author:DaughertyC KCK, pubmed-author:MinamiHH, pubmed-author:RatainM JMJ, pubmed-author:SieglerMM, pubmed-author:StadlerW MWM, pubmed-author:VogelzangN JNJ
pubmed:issnType	Print
pubmed:volume	16
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2305-12
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:9667244-Adult, pubmed-meshheading:9667244-Aged, pubmed-meshheading:9667244-Antineoplastic Agents, Phytogenic, pubmed-meshheading:9667244-Clinical Trials, Phase I as Topic, pubmed-meshheading:9667244-Cohort Studies, pubmed-meshheading:9667244-Comprehension, pubmed-meshheading:9667244-Disclosure, pubmed-meshheading:9667244-Drug Administration Schedule, pubmed-meshheading:9667244-Ethics, Medical, pubmed-meshheading:9667244-Feasibility Studies, pubmed-meshheading:9667244-Female, pubmed-meshheading:9667244-Humans, pubmed-meshheading:9667244-Informed Consent, pubmed-meshheading:9667244-Male, pubmed-meshheading:9667244-Middle Aged, pubmed-meshheading:9667244-Nontherapeutic Human Experimentation, pubmed-meshheading:9667244-Paclitaxel, pubmed-meshheading:9667244-Patient Participation, pubmed-meshheading:9667244-Patient Selection, pubmed-meshheading:9667244-Personal Autonomy, pubmed-meshheading:9667244-Research Subjects, pubmed-meshheading:9667244-Risk Assessment, pubmed-meshheading:9667244-Vinblastine
pubmed:year	1998
pubmed:articleTitle	Study of cohort-specific consent and patient control in phase I cancer trials.
pubmed:affiliation	Department of Medicine, the MacLean Center for Clinical Medical Ethics, University of Chicago, IL 60637-1470, USA. ckdaughe@mcis.bsd.uchicago.edu
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase I